Prof Ivan Gout


Personal Profile

Name: Ivan Gout Email:
Title: Prof Tel: 0207-679-4482
Department: Structural & Molecular Biology Fax: 020 7679 7193
Position: Professor of Cancer Biochemistry Address: Darwin Building, Gower St, London, WC1E 6BT
Research Domain: Cancer, Personalised Medicine Web Page: Personal Web Page


Research Description

I graduated as an MD at Lviv Medical University (Ukraine) in 1983 with a great passion to become a surgeon in oncology. Thinking that a PhD in experimental oncology would help to realise my dream, I obtained my doctorate at the Institute of Experimental Oncology, National Academy of Sciences of Ukraine in 1987. A fellowship from the International Agency for Research on Cancer (IARC) took me even further from clinical oncology and also from the Ukraine. I arrived in London on the first wave of perestroika and began my post-doctoral training in Jim Woodgett's laboratory at the Ludwig Institute for Cancer Research (UCL Branch). Subsequently I worked in Mike Waterfield's laboratory at the same Institute studying signal transduction via the PI3 kinase pathway. In 1998, I started my own group at the Ludwig Institute for Cancer Research, focussing on the regulation of growth via the S6 kinase pathway. Since 2003, I have been a Professor in this Department, where I have an active research group working on signal transduction via the mTOR/S6K pathway in normal and cancer cells. Since 1998, I have also managed a laboratory (jointly with Prof. V. Filonenko) at the Institute of Molecular Biology and Genetics in Ukraine, which is affiliated to the Ludwig Institute for Cancer Research through the Kerr Programme. My current research interests are in the regulation of cell growth and metabolism in normal and cancer cells. We focus mainly on: a) elucidation of cell growth, metabolism and proliferation via the mTOR/S6K pathway; b) the role of Coenzyme A and its derivatives in cellular metabolism and gene expression. In collaboration with academic and industrial partners, we pursue the development of novel diagnostic and therapeutic approaches for cancer. Research Interest The main focus of our research is the study of basic mechanisms by which cell growth and metabolism are regulated in normal and cancer cells. There are two major areas of interest in the laboratory: a) regulation of cell growth, metabolism and proliferation via the mTOR/S6K pathway; b) the role of Coenzyme A and its derivatives in cellular metabolism and gene expression. The development of novel diagnostic and therapeutic approaches for cancer is the ultimate goal of our research, which we pursue through collaboration with academic and industrial partners. a) Regulation of cell growth, metabolism and proliferation via mTOR/S6K pathway Molecular cloning of the second isoform of S6 kinase, which we termed S6K? or S6K2, was a cornerstone for establishing an independent research platform that further extended into signalling via the mTOR pathway. The mTOR (mammalian target of rapamycin) is a central regulator of an evolutionary conserved signalling pathway which controls cellular metabolism, growth and proliferation. These functions are mediated through the formation of multienzyme complexes and the phosphorylation of key signalling molecules, such as protein kinases S6K and PKB/Akt, and a negative regulator of translation, 4E-BP1. Deregulation of mTOR-coordinated signalling has been associated with various human pathologies, including diabetes, inflammation and cancer. Rapamycin, a naturally occurring mTOR inhibitor, and its homologues are currently being tested as anti-cancer drugs in numerous clinical trials. The mechanisms by which the mTOR/S6K pathway controls energy metabolism, cell growth and proliferation are studied in the lab at the biochemical, cellular and organism level. To elucidate downstream signalling from S6K1 and S6K2, we employ DNA microarrays, siRNA knockdowns, yeast two hybrid screening and affinity purification followed by mass spectrometry. Using these approaches we have identified a panel of novel S6K binding partners/substrates, which link S6K to the regulation of cellular metabolism and transcription.

Research Activities

Cell signalling through phospholipases, kinases and G-proteins during differentiation and secretion.

Cellular mechanisms underlying neurodegeneration

Effect of Tumour Biology on Therapeutic Response

Genetics of ageing and age-related disease in Caenorhabditis elegans

Regulation of growth and energy metabolism via the mTOR/S6K pathway in normal and cancer cells

Education Description

I am the Graduate Admission Tutor in the Department, the Lead Tutor in Biotechnology for the MRes in Biosciences and course organizer BIOL2014. I lecture and give tutorials on growth regulation and cell signalling to second and third year students. I also supervise third year students for laboratory projects. Course organizer: FEBS Advances Lecture and Practical course on fundamental techniques in mammalian cell biology, Kyiv, Ukraine, 2009 FEBS Advances Lecture and Practical course on fundamental techniques in mammalian cell biology, UCL, London, 2011

UCL Collaborators

Prof Barbara Pedley; Prof David Gems; Prof Parmjit Jat; Prof Daniel Hochhauser; Prof Hans Stauss; Prof Dame Linda Partridge; Prof John Hardy; Prof Quentin Pankhurst; Prof John Collinge; Prof David Linch; Prof Sarah Tabrizi; Dr Peter-Christian Kloehn; Prof Paul Beard; Prof Geraint Thomas; Prof Chris Boshoff; Dr Erik Arstad; Dr Stephanie Schorge; Prof Mike O'hare; Prof Paul Driscoll

External Collaborators



    • Ismail HM, Myronova O, Tsuchiya Y, Niewiarowski A, Tsaneva I, Gout I (2013). Identification of the general transcription factor Yin Yang 1 as a novel and specific binding partner for S6 kinase 2.. Cell Signal, 25(5), 1054 - 1063. doi:10.1016/j.cellsig.2013.02.002


    • Fenton TR, Gout IT (2011). Functions and regulation of the 70kDa ribosomal S6 kinases.. Int J Biochem Cell Biol, 43(1), 47 - 59. doi:10.1016/j.biocel.2010.09.018
    • Fenton TR, Gout IT (2011). Functions and regulation of the 70 kDa ribosomal S6 kinases. INT J BIOCHEM CELL B, 43(1), 47 - 59. doi:10.1016/j.bioce1.2010.09.018


    • Goh ET, Pardo OE, Michael N, Niewiarowski A, Totty N, Volkova D, Tsaneva IR, Seckl MJ, Gout I (2010). Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway. J.Biol.Chem., 285(22), 17065 - 17076.
    • Fenton TR, Gwalter J, Cramer R, Gout IT (2010). S6K1 is acetylated at lysine 516 in response to growth factor stimulation.. Biochem Biophys Res Commun, 398(3), 400 - 405. doi:10.1016/j.bbrc.2010.06.081
    • Gnjatic S, Cao Y, Reichelt U, Yekebas EF, Nolker C, Marx AH, Erbersdobler A, Nishikawa H, Hildebrandt Y, Bartels K, Horn C, Stahl T, Gout I, Filonenko V, Ling KL, Cerundolo V, Luetkens T, Ritter G, Friedrichs K, Leuwer R, Hegewisch-Becker S, Izbicki JR, Bokemeyer C, Old LJ, Atanackovic D (2010). NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. Int.J.Cancer, 127(2), 381 - 393.
    • Kiyamova R, Kostianets O, Malyuchik S, Filonenko V, Usenko V, Gurtovyy V, Khozayenko Y, Antonuk S, Old L, Gout I (2010). Identification of Tumor-Associated Antigens from Medullary Breast Carcinoma by a Modified SEREX Approach. Mol.Biotechnol., , - .
    • Breus O, Panasyuk G, Gout IT, Filonenko V, Nemazanyy I (2010). CoA Synthase is phosphorylated on tyrosines in mammalian cells, interacts with and is dephosphorylated by Shp2PTP.. Mol Cell Biochem, 335(1-2), 195 - 202. doi:10.1007/s11010-009-0255-6
    • Fenton TR, Gwalter J, Ericsson J, Gout IT (2010). Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases in vitro and in vivo.. Int J Biochem Cell Biol, 42(2), 359 - 366. doi:10.1016/j.biocel.2009.11.022
    • Gorbenko O, Panayotou G, Zhyvoloup A, Volkova D, Gout I, Filonenko V (2010). Identification of novel PTEN-binding partners: PTEN interaction with fatty acid binding protein FABP4. Mol.Cell Biochem., 337(1-2), 299 - 305.


    • Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirabosco R, Flanagan AM (2009). Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br.J.Cancer, 100(9), 1406 - 1414.
    • Gryshkova V, Goncharuk I, Gurtovyy V, Khozhayenko Y, Nespryadko S, Vorobjova L, Usenko V, Gout I, Filonenko V, Kiyamova R (2009). The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer. Exp.Oncol., 31(1), 37 - 42.
    • Gwalter J, Wang ML, Gout I (2009). The ubiquitination of ribosomal S6 kinases is independent from the mitogen-induced phosphorylation/activation of the kinase. Int.J.Biochem.Cell Biol., 41(4), 828 - 833.
    • Hurd PJ, Bannister AJ, Halls K, Dawson MA, Vermeulen M, Olsen JV, Ismail H, Somers J, Mann M, Owen-Hughes T, Gout I, Kouzarides T (2009). Phosphorylation of histone H3 Thr-45 is linked to apoptosis. J.Biol.Chem., 284(24), 16575 - 16583.
    • Gorbenko O, Ovcharenko G, Volkova D, Mayilo D, Gaman N, Khozhayenko Y, Usenko V, Gout I, Filonenko V (2009). Monoclonal antibodies with selective specificity towards different glycosylation isoforms of FGFR1. Hybridoma (Larchmt.), 28(4), 287 - 293.
    • Gorbenko O, Ovcharenko G, Klymenko T, Zhyvoloup O, Gaman N, Volkova D, Gout I, Filonenko V (2009). Generation of monoclonal antibody targeting fibroblast growth factor receptor 3. Hybridoma (Larchmt.), 28(4), 295 - 300.
    • Breus O, Panasyuk G, Gout IT, Filonenko V, Nemazanyy I (2009). CoA synthase is in complex with p85alphaPI3K and affects PI3K signaling pathway.. Biochem Biophys Res Commun, 385(4), 581 - 585. doi:10.1016/j.bbrc.2009.05.102
    • Panasyuk G, Nemazanyy I, Zhyvoloup A, Filonenko V, Davies D, Robson M, Pedley RB, Waterfield M, Gout I (2009). mTORbeta splicing isoform promotes cell proliferation and tumorigenesis. J.Biol.Chem., 284(45), 30807 - 30814.
    • Kovaleva V, Kiyamova R, Cramer R, Krynytskyy H, Gout I, Filonenko V, Gout R (2009). Purification and molecular cloning of antimicrobial peptides from Scots pine seedlings. Peptides, 30(12), 2136 - 2143.


    • Wang ML, Panasyuk G, Gwalter J, Nemazanyy I, Fenton T, Filonenko V, Gout I (2008). Regulation of ribosomal protein S6 kinases by ubiquitination. Biochem.Biophys.Res.Commun., 369(2), 382 - 387.
    • Kiyamova R, Gryshkova V, Ovcharenko G, Lituyev D, Malyuchik S, Usenko V, Khozhayenko Y, Gurtovyy V, Yin B, Ritter G, Old L, Filonenko V, Gout I (2008). Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b. Hybridoma (Larchmt.), 27(4), 277 - 284.
    • Nemazanyy I, Breus O, Gout I, Filonenko V, Panasyuk G (2008). Generation and characterization of monoclonal antibodies to mTOR kinase. Hybridoma (Larchmt.), 27(5), 395 - 399.
    • Yin BW, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, Bhaskaran N, Souchelnytskyi S, Hellman U, Filonenko V, Jungbluth AA, Odunsi K, Lloyd KO, Old LJ, Ritter G (2008). Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun., 8, 3 - .
    • Panasyuk G, Nemazanyy I, Filonenko V, Gout I (2008). Ribosomal protein S6 kinase 1 interacts with and is ubiquitinated by ubiquitin ligase ROC1. Biochem.Biophys.Res.Commun., 369(2), 339 - 343.


    • Malanchuk O, Palchevskyy S, Ovcharenko G, Gwalter J, Pozur V, Gout I, Filonenko V (2007). Generation and characterization of monoclonal antibodies against tuberous sclerosis complex 2. Hybridoma (Larchmt.), 26(4), 259 - 266.
    • Jager D, Filonenko V, Gout I, Frosina D, Eastlake-Wade S, Castelli S, Varga Z, Moch H, Chen YT, Busam KJ, Seil I, Old LJ, Nissan A, Frei C, Gure AO, Knuth A, Jungbluth AA (2007). NY-BR-1 is a differentiation antigen of the mammary gland. Appl.Immunohistochem.Mol.Morphol., 15(1), 77 - 83.
    • Seckl MJ, Pardo OE, Sebire N, Bowen F, Gout I, Marias R, Downward J (2007). A novel complex comprising BRaf, PKC epsilon and S6K2 mediates the pro-survival effects of FGF-2 in small cell lung cancer cells. doi:10.1038/sj.emboj.7601198


    • Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, Bowen F, Parker PJ, Filonenko VV, Gout IT, Sebire N, Marais R, Downward J, Seckl MJ (2006). FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. The EMBO Journal, 25(13), 3078 - 3088. doi:10.1038/sj.emboj.7601198
    • Gout EA (2006). Regulation of S6 Kinase protein kinase 2 and related methods.
    • Proto-Siqueira R, Figueiredo-Pontes LL, Panepucci RA, Garcia AB, Rizzatti EG, Nascimento FM, Ishikawa HC, Larson RE, Falcao RP, Simpson AJ, Gout I, Filonenko V, Rego EM, Zago MA (2006). PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma.. Leukemia Research, 30(11), 1333 - 1339.
    • Gorbenko O, Filonenko V, Gout I (2006). Generation and characterization of monoclonal antibodies against FABP4. Hybridoma, 25(2), 86 - 90. doi:10.1089/hyb.2006.25.86
    • Rebholz H, Panasyuk G, Fenton T, Nemazanyy I, Valovka T, Flajolet M, Ronnstrand L, Stephens L, West A, Gout IT (2006). Receptor association and tyrosine phosphorylation of S6 kinases. Federation of European Biochemical Societies Letters, 273(9), 2023 - 2036. doi:10.1111/j.1742-4658.2006.05219.x
    • Nemazanyy I, Panasyuk G, Breus O, Zhyvoloup A, Filonenko V, Gout IT (2006). Identification of a novel CoA synthase isoform, which is primarily expressed in the brain. Biochemical and Biophysical Research Communications, 341(4), 995 - 1000..
    • Panasyuk G, Nemazanyy I, Zhyvoloup A, Bretner M, Litchfield D, Filonenko V, Gout I (2006). Nuclear export of S6K1 II is regulated by protein kinase CK2 phosphorylation at ser 17.. Journal of Biological Chemistry, 281(42), 31188 - 31201. doi:10.1074/jbc.M602618200


    • Lyzogubov VV, Usenko VS, Gurtovy VA, Nemazanyy IO, Gout IT, Filonenko VV (2005). Immunohistochemical localization of Coenzyme A synthase in normal rat tissues.
    • de Figueiredo-Pontes LL, do Nascimento FM, Lima RSDE, Proto-Siqueira R, Garcia AB, Matos DM, Gout IT, Filonenko VV, Zago MA, Falcao RP, Rego EM (2005). Analysis of PRAME protein expression in normal lymphoid tissues and during B ontogenesis..
    • Malanchuk OM, Pozur V, Panasyuk GG, Nemazanyy IO, Filonenko VV, Gout IT, Palchevskyy SS (2005). Identification of novel binding partners for tuberous sclerosis complex 2 (TSC2) by yeast two-hybrid approach.. Experimental Oncology, 27(3), 186 - 190.
    • Panasyuk G, Nemazanyy I, Ovcharenko G, Lyzogubov V, Gout I, Filonenko V (2005). Generation and characterization of monoclonal antibodies to protein kinase 2 (CK2) beta subunit.. Hybridoma (Larchmt)., 24(4), 206 - 210.


    • Filonenko VV, Tytarenko R, Azatjan SK, Savinska LO, Gaydar YA, Gout IT, Usenko VS, Lyzogubov VV (2004). Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors.. Experimental Oncology, 26(4), 294 - 299.
    • Nemazanyy I, Panasyuk G, Zhyvoloup A, Panayotou G, Gout IT, Filonenko V (2004). Specific interaction between S6K1 and CoA synthase: a potential link between the mTOR/S6K pathway, CoA biosynthesis and energy metabolism.. Federation of European Biochemical Societies Letters, 578(3), 357 - 362.
    • Savinska LO, Lyzogubov VV, Usenko VS, Ovcharenko GV, Gorbenko ON, Rodnin MV, Vudmaska MI, Pogribniy PV, Kyyamova RG, Panasyuk GG, Nemazanyy IO, Malets MS, Palchevskyy SS, Gout IT, Filonenko VV (2004). Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors.. Eksp Onkol, 26(1), 24 - 30.
    • Lyzogubov VV, Lytvyn DI, Dudchenko TM, Lubchenko NV, Pogrybniy PV, Nespryadko SV, Vinnitska AB, Usenko VS, Gout IT, Filonenko VV (2004). Immunohistochemical analysis of S6K1 and S6K2 expression in endometrial adenocarcinomas.. Exp Oncol, 26(4), 287 - 293.
    • Gorbenko O, Kuznetsov V, Kukharenko O, Zhyvoloup A, Panasyuk G, Nemazanyy I, Filonenko V, Gout I (2004). Identification of a novel binding partners for tumor suppressor PTEN by a yeast two-hybrid approach.. Experimental Oncology, 26(1), 15 - 19.
    • Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.. The Journal of Cell Biology, 166(2), 213 - 223.
    • Azatyan S, Lyzogubov VV, Tytarenko RG, Savinska LO, Gaydar YA, Gout IT, Filonenko VV, Usenko VS (2004). Immunohistochemical study of P70 S6 kinase protein overexpression in human malignant breast tumors. ANN ONCOL, 15, 21 - 21.


    • Kingsbury SR, Gout IT (2003). Phosphoinositide 3-kinases and cancer. EXP ONCOL, 25(1), 3 - 15.
    • Valovka T, Verdier F, Cramer R, Zhyvoloup A, Fenton T, Rebholz H, Wang ML, Gzhegotsky M, Lutsyk A, Matsuka G, Filonenko V, Wang L, Proud CG, Parker PJ, Gout IT (2003). Protein kinase C phosphorylates ribosomal protein S6 kinase ßII and regulates its subcellular localization. Molecular and Cellular Biology, 23(3), 852 - 863. doi:10.1128/MCB.23.3.852-863.2003
    • Zhyvoloup A, Nemazanyy I, Panasyuk G, Valovka T, Fenton T, Rebholz H, Wang ML, Foxon R, Lyzogubov V, Usenko V, Kyyamova R, Gorbenko O, Matsuka G, Filonenko V, Gout IT (2003). Subcellular Localization and Regulation of Coenzyme A Synthase. Journal of Biological Chemistry, 278(50), 50316 - 50321. doi:10.1074/jbc.M307763200
    • Kit YY, Drel VR, Petriv OI, Kovalyova VA, Shuvaeva GY, Palivoda OY, Vovk EI, Bobak YP, Rzeszowska-Wolny J, Gout IT, Buchman VL, Drobot LB (2003). Adaptor protein Ruk1 forms protein-protein complexes with endonuclease activity in HEK293 cells. Biochemistry (Moscow), 68(7), 810 - 815.
    • Garifulin OM, Kykot VO, Gridina NY, Kijamova RG, Gout IT, Filonenko VV (2003). Serex-analysis of three colon cancer cases. EXP ONCOL, 25(2), 128 - 131.


    • Zhyvoloup A, Nemazanyy I, Babych O, Panasyuk G, Pobigailo N, Vudmaska M, Naidenov V, Kukharenko O, Palchevskii S, Savinska L, Ovcharenko G, Verdier F, Valovka T, Fenton T, Rebholz H, Wang M, Shepherd PR, Matusuka G, Filonenko V, Gout IT (2002). Molecular cloning of CoA synthase: a missing link in CoA biosynthesis. Journal of Biological Chemistry, 277, 22107 - 22110. doi:10.1074/jbc.C200195200
    • Buchman V, Luke C, Borthwick E, Gout IT, Ninkina N (2002). Organisation of the mouse Ruk locus and expression of isoforms in mouse tissues. Gene, 295(1), 13 - 17.
    • Verdier F, Valovka T, Zhyvoloup A, Drobot LB, Buchman V, Waterfield MD, Gout IT (2002). Ruk is ubiquinated but not degraded by the proteasome. European Journal of Biochemistry, 269(14), 3402 - 3408.
    • Vigontina O, Efimenko O, Yakovenko L, Kiyamova R, Filonenko V, Gout IT, Ros N, Kosey N, Tatarchuk T, Sidoril L, Matsuka G (2002). Chaperon HSP-60 as autoantigen in the development of dyshormonal breast diseases. Experimental Oncology, 24, 112 - 115.


    • Grisendi S, Chambraud B, Gout I, Comoglio PM, Crepaldi T (2001). Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor. Journal of Biological Chemistry, 276(49), 46632 - 46638.
    • Pardo O, Arcaro A, Salerno T, Tetley T, Valovka T, Gout I, Seckl M (2001). Novel cross-talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene, 20(52), 7658 - 7667.
    • Zhyvoloup O, Nemazanyy I, Pobigaylo N, Panasyuk G, Pal'chevskii S, Kukharenko O, Gout I, Filonenko V (2001). The search for novel S6K binding partners by yeast two-hybrid system. Biopolymers and Cell, 16(5), 465 - 471.
    • Wang L, Gout I, Proud CG (2001). Cross-talk between the Erk and p70 S6K signalling pathways: MEK-dependent activation of S6K2 in cardiomyocytes. Journal of Biological Chemistry, 276(35), 32670 - 32677.
    • Scanlan M, Gout I, Gordon C, Williamson B, Stockert E, Gure A, Jager D, Chen Y-T, Mackay A, O'Hare M, Old L (2001). Humoral immunity to human breast cancer: antigen definition and quantative analysis of mRNA expression. Cancer Immunity, 1, 4 - .
    • Savinskaya L, Kiyamova RG, Ovcharenko GV, Gout I, Filonenko V (2001). Comparative characterisation of S6 kinase alpha and beta isoforms expression in mammalian tissues. Biopolymers and Cell, 17(5), 405 - 411.
    • Minami T, Hara K, Oshiro N, Ueoku S, Yoshino Y, Tokunaga C, Shirai Y, Saito N, Gout I, Yonezawa K (2001). Distinct regulatory mechanism for p70 S6 kinase beta from that for p70 S6 kinase alpha. Gene Cells, 6(11), 1003 - 1015.


    • (2000). Negative regulation of PI 3-kinase by Ruk, a novel adaptor protein. The EMBO Journal, 19(15), 4015 - 4025.
    • Rodnin NV, Tykhonkova IO, Nemazany IO, Gorlova LM, Komissarenko IV, Palchevskiy SS, Kuharenko OP, Drobot LB, Matsuka GH, Filonenko VV, Gout IT (2000). Serological identification of autoimmune reactive antigens in human thyroid cancer cells. EXP ONCOL, 22(3), 135 - 138.
    • Rader C, Ritter G, Nathan S, Elia M, Gout I, Jungbluth AA, Cohen LS, Welt S, Old LJ, Barbas CF (2000). The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. Journal of Biological Chemistry, 275(18), 13668 - 13676.


    • Pogrebnoy PV, Kukharenko AP, Tykhonkova IA, Pal'chevskiy SS, Savinskaya LA, Pogrebnaya AP, Valevka TI, Markeeva NV, Soldatkina MA, Matsuka GK, Gout IT, Filonenko VV (1999). Generation and characterization of monoclonal antibodies to p70S6 kinase alpha. EXP ONCOL, 21(3-4), 232 - 238.
    • Banin S, Gout I, Brickell P (1999). Interaction between Wiskott-Aldrich Syndrome protein (WASP) and the Fyn protein-tyrosine kinase. Molecular Biology Reports, 26(3), 173 - 177.
    • Valovka T, Filonenko V, Palchevsky S, Velikiy M, Drobot L, Waterfield MD, Matsuka G, Gout I (1999). Functional and regulatory properties of p70S6 kinase beta. Biopolimery i kletka, 15(5), 1 - 7.


    • Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998). A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J.Exp.Med., 187(8), 1349 - 1354.
    • Arcaro A, Volinia S, Zvelebil MJ, Stein R, Watton SJ, Layton MJ, Gout I, Ahmadi K, Downward J, Waterfield MD (1998). Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J.Biol.Chem., 273(49), 33082 - 33090.
    • Gout I, Minami T, Hara K, Tsujishita Y, Filonenko V, Waterfield MD, Yonezawa K (1998). Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase beta containing a proline-rich region. J.Biol.Chem., 273(46), 30061 - 30064.
    • Scharenberg AM, El-Hillal O, Fruman DA, Beitz LO, Li Z, Lin S, Gout I, Cantley LC, Rawlings DJ, Kinet JP (1998). Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J., 17(7), 1961 - 1972.
    • Arcaro A, Volinia S, Zvelebil JM, Stein R, Watton SJ, Layton MJ, Gout I, Ahmadi K, Downward J, Waterfield MD (1998). Human PI 3-Kinase C2á - the Role of Calcium and the C2 Domain in Enzyme Activity. Journal of Biological Chemistry, 273, 33082 - 33090.
    • Gout I, Minami T, Hara K, Tsujishita Y, Filonenko V, Waterfield MD, Yonezawa K (1998). Molecular cloning and characterization of a novel p70 S6 kinase, containing a proline-rich region. Journal of Biological Chemistry, 273(46), 30061 - 30064.


    • Kinnon C, Cory GOC, MacCarthy-Morrogh L, Banin S, Gout I, Lovering RC, Brickell PM (1997). The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways. Biochemical Society Transactions, 25, 648 - 650.


    • Salim K, Bottomley MJ, Querfurth E, Zvelebil MJ, Gout I, Scaife R, Margolis RL, Gigg R, Smith CI, Driscoll PC, Waterfield MD, Panayotou G (1996). Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. EMBO J., 15(22), 6241 - 6250.
    • Cory GO, Carthy-Morrogh L, Banin S, Gout I, Brickell PM, Levinsky RJ, Kinnon C, Lovering RC (1996). Evidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathways. J.Immunol., 157(9), 3791 - 3795.
    • Banin S, Truong O, Katz DR, Waterfield MD, Brickell PM, Gout I (1996). Wiskott-Aldrich syndrome protein (WASp) is a binding partner for c-Src family protein-tyrosine kinases. Curr.Biol., 6(8), 981 - 988.
    • Kilgour E, Gout I, Anderson NG (1996). Requirement for phosphoinositide 3-OH kinase in growth hormone signalling to the mitogen-activated protein kinase and p70s6k pathways. Biochem.J., 315 ( Pt 2), 517 - 522.
    • Okabayashi Y, Sugimoto Y, Totty NF, Hsuan J, Kido Y, Sakaguchi K, Gout I, Waterfield MD, Kasuga M (1996). Interaction of Shc with adaptor protein adaptins. Journal of Biological Chemistry, 271(9), 5265 - 5269. doi:10.1074/jbc.271.9.5265
    • Zvelebil MJ, MacDougall L, Leevers S, Volinia S, Vanhaesebroeck B, Gout I, Panayotou G, Domin J, Stein R, Pages F, . (1996). Structural and functional diversity of phosphoinositide 3-kinases. Philos.Trans.R.Soc.Lond B Biol.Sci., 351(1336), 217 - 223.
    • Kitamura T, Kitamura Y, Yonezawa K, Totty NF, Gout I, Hara K, Waterfield MD, Sakaue M, Ogawa W, Kasuga M (1996). Molecular cloning of p125Nap1, a protein that associates with an SH3 domain of Nck. Biochem.Biophys.Res.Commun., 219(2), 509 - 514.


    • Guruprasad L, Dhanaraj V, Timm D, Blundell TL, Gout I, Waterfield MD (1995). The crystal structure of the N-terminal SH3 domain of Grb2. J.Mol.Biol., 248(4), 856 - 866.
    • Zhang J, Zhang J, Benovic JL, Sugai M, Wetzker R, Gout I, Rittenhouse SE (1995). Sequestration of a G-protein beta gamma subunit or ADP-ribosylation of Rho can inhibit thrombin-induced activation of platelet phosphoinositide 3-kinases. J.Biol.Chem., 270(12), 6589 - 6594.


    • Timm D, Salim K, Gout I, Guruprasad L, Waterfield M, Blundell T (1994). Crystal structure of the pleckstrin homology domain from dynamin. Nat.Struct.Biol., 1(11), 782 - 788.
    • Downing AK, Driscoll PC, Gout I, Salim K, Zvelebil MJ, Waterfield MD (1994). Three-dimensional solution structure of the pleckstrin homology domain from dynamin. Curr.Biol., 4(10), 884 - 891.
    • Blume-Jensen P, Ronnstrand L, Gout I, Waterfield MD, Heldin CH (1994). Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. J.Biol.Chem., 269(34), 21793 - 21802.
    • Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature, 370(6490), 527 - 532.
    • Ando A, Yonezawa K, Gout I, Nakata T, Ueda H, Hara K, Kitamura Y, Noda Y, Takenawa T, Hirokawa N, . (1994). A complex of GRB2-dynamin binds to tyrosine-phosphorylated insulin receptor substrate-1 after insulin treatment. EMBO J., 13(13), 3033 - 3038.
    • Cockcroft S, Thomas GM, Fensome A, Geny B, Cunningham E, Gout I, Hiles I, Totty NF, Truong O, Hsuan JJ (1994). Phospholipase D: a downstream effector of ARF in granulocytes. Science, 263(5146), 523 - 526.
    • Stephens L, Cooke FT, Walters R, Jackson T, Volinia S, Gout I, Waterfield MD, Hawkins PT (1994). Characterization of a phosphatidylinositol-specific phosphoinositide 3-kinase from mammalian cells. Curr.Biol., 4(3), 203 - 214.
    • Dhand R, Hiles I, Panayotou G, Roche S, Fry MJ, Gout I, Totty NF, Truong O, Vicendo P, Yonezawa K, . (1994). PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J., 13(3), 522 - 533.
    • Dhand R, Hara K, Hiles I, Bax B, Gout I, Panayotou G, Fry MJ, Yonezawa K, Kasuga M, Waterfield MD (1994). PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J., 13(3), 511 - 521.
    • Finan P, Shimizu Y, Gout I, Hsuan J, Truong O, Butcher C, Bennett P, Waterfield MD, Kellie S (1994). An SH3 domain and proline-rich sequence mediate an interaction between two components of the phagocyte NADPH oxidase complex. Journal of Biological Chemistry, 269(19), 13752 - 13755.
    • Scaife R, Gout I, Waterfield MD, Margolis RL (1994). Growth factor-induced binding of dynamin to signal transduction proteins involves sorting to distinct and separate proline-rich dynamin sequences. EMBO J., 13(11), 2574 - 2582.


    • Gout I, Dhand R, Hiles ID, Fry MJ, Panayotou G, Das P, Truong O, Totty NF, Hsuan J, Booker GW, . (1993). The GTPase dynamin binds to and is activated by a subset of SH3 domains. Cell, 75(1), 25 - 36.
    • Nussey SS, Soo SC, Gibson S, Gout I, White A, Bain M, Johnstone AP (1993). Isolated congenital ACTH deficiency: a cleavage enzyme defect?. Clin.Endocrinol.(Oxf), 39(3), 381 - 385.
    • End P, Gout I, Fry MJ, Panayotou G, Dhand R, Yonezawa K, Kasuga M, Waterfield MD (1993). A biosensor approach to probe the structure and function of the p85 alpha subunit of the phosphatidylinositol 3-kinase complex. J.Biol.Chem., 268(14), 10066 - 10075.
    • Booker GW, Gout I, Downing AK, Driscoll PC, Boyd J, Waterfield MD, Campbell ID (1993). Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase. Cell, 73(4), 813 - 822.
    • Reif K, Gout I, Waterfield MD, Cantrell DA (1993). Divergent regulation of phosphatidylinositol 3-kinase P85 alpha and P85 beta isoforms upon T cell activation. J.Biol.Chem., 268(15), 10780 - 10788.
    • Panayotou G, Gish G, End P, Truong O, Gout I, Dhand R, Fry MJ, Hiles I, Pawson T, Waterfield MD (1993). Interactions between SH2 domains and tyrosine-phosphorylated platelet-derived growth factor beta-receptor sequences: analysis of kinetic parameters by a novel biosensor-based approach. Mol.Cell Biol., 13(6), 3567 - 3576.


    • Gout I, Dhand R, Panayotou G, Fry MJ, Hiles I, Otsu M, Waterfield MD (1992). Expression and characterization of the p85 subunit of the phosphatidylinositol 3-kinase complex and a related p85 beta protein by using the baculovirus expression system. Biochem.J., 288 ( Pt 2), 395 - 405.
    • Panayotou G, Bax B, Gout I, Federwisch M, Wroblowski B, Dhand R, Fry MJ, Blundell TL, Wollmer A, Waterfield MD (1992). Interaction of the p85 subunit of PI 3-kinase and its N-terminal SH2 domain with a PDGF receptor phosphorylation site: structural features and analysis of conformational changes. EMBO J., 11(12), 4261 - 4272.
    • Fry MJ, Panayotou G, Dhand R, Ruiz-Larrea F, Gout I, Nguyen O, Courtneidge SA, Waterfield MD (1992). Purification and characterization of a phosphatidylinositol 3-kinase complex from bovine brain by using phosphopeptide affinity columns. Biochem.J., 288 ( Pt 2), 383 - 393.
    • Bardelli A, Maina F, Gout I, Fry MJ, Waterfield MD, Comoglio PM, Ponzetto C (1992). Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. Oncogene, 7(10), 1973 - 1978.
    • Harfst E, Johnstone AP, Gout I, Taylor AH, Waterfield MD, Nussey SS (1992). The use of the amplifiable high-expression vector pEE14 to study the interactions of autoantibodies with recombinant human thyrotrophin receptor. Mol.Cell Endocrinol., 83(2-3), 117 - 123.
    • Volinia S, Patracchini P, Otsu M, Hiles I, Gout I, Calzolari E, Bernardi F, Rooke L, Waterfield MD (1992). Chromosomal localization of human p85 alpha, a subunit of phosphatidylinositol 3-kinase, and its homologue p85 beta. Oncogene, 7(4), 789 - 793.
    • Hiles ID, Otsu M, Volinia S, Fry MJ, Gout I, Dhand R, Panayotou G, Ruiz-Larrea F, Thompson A, Totty NF, . (1992). Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell, 70(3), 419 - 429.
    • Booker GW, Breeze AL, Downing AK, Panayotou G, Gout I, Waterfield MD, Campbell ID (1992). Structure of an SH2 domain of the p85 alpha subunit of phosphatidylinositol-3-OH kinase. Nature, 358(6388), 684 - 687.


    • Otsu M, Hiles I, Gout I, Fry MJ, Ruiz-Larrea F, Panayotou G, Thompson A, Dhand R, Hsuan J, Totty N, . (1991). Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell, 65(1), 91 - 104.